Response to preoperative therapy in upper gastrointestinal cancers

Annals of Surgical Oncology

Volumn 16, Issue 4, 2009, Pages 878-886

  Brücher, Björn L D M ^a   Swisher, Stephen G ^b   Königsrainer, Alfred ^a   Zieker, Derek ^a   Hartmann, Jörg ^a   Stein, Hubert ^c   Kitagawa, Yuko ^d   Law, Simon ^e   Ajani, Jaffer A ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF SALZBURG   (Austria)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HISTOPATHOLOGY; HUMAN; MEDICAL EDUCATION; MEDICAL LITERATURE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; TREATMENT PLANNING; TREATMENT RESPONSE;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; HUMANS; NEOADJUVANT THERAPY; SENSITIVITY AND SPECIFICITY;

EID: 62149090674     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0315-x     Document Type: Article

References (69)

1. A Jemal T Murray E Ward A Samuels RC Tiwari A Ghafoor 2005 Cancer statistics, 2005 CA Cancer J Clin 55 1 10 30
2. WJ Blot JK McLaughlin 1999 The changing epidemiology of esophageal cancer Semin Oncol 26 5 Suppl 15 2 8
3. M van Blankenstein CW Looman WC Hop P Bytzer 2005 The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus: Barrett's esophagus makes a difference Am J Gastroenterol 100 4 766 774
4. H Pohl HG Welch 2005 The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence J Natl Cancer Inst 97 2 142 146
5. JB Hulscher JW van Sandick AG de Boer BP Wijnhoven JG Tijssen P Fockens 2002 Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus N Engl J Med 347 21 1662 1669
6. BLDM Brücher HJ Stein M Werner JR Siewert 2001 Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma Cancer 92 8 2228 2233
7. HJ Stein BH von Rahden JR Siewert 2005 Survival after oesophagectomy for cancer of the oesophagus Langenbecks Arch Surg 390 4 280 285
8. J Jin Z Liao Z Zhang J Ajani S Swisher JY Chang 2004 Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery Int J Radiat Oncol Biol Phys 60 2 427 436
9. DH Ilson 2003 Oesophageal cancer: new developments in systemic therapy Cancer Treat Rev 29 6 525 532
10. R Greil HJ Stein 2007 Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer? Lancet Oncol 8 3 189 190
11. M Stahl M Stuschke N Lehmann HJ Meyer MK Walz S Seeber 2005 Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus J Clin Oncol 23 10 2310 2317
12. JF Bosset M Gignoux JP Triboulet E Tiret G Mantion D Elias 1997 Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus N Engl J Med 337 3 161 167
13. BH Burmeister BM Smithers V Gebski L Fitzgerald RJ Simes P Devitt 2005 Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial Lancet Oncol 6 9 659 668
14. E Le Prise PL Etienne B Meunier G Maddern M Ben Hassel D Gedouin 1994 A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus Cancer 73 7 1779 1784
15. K Nygaard S Hagen HS Hansen R Hatlevoll R Hultborn A Jakobsen 1992 Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy The second Scandinavian trial in esophageal cancer World J Surg 16 6 1104 1109 discussion 1110
16. SG Urba MB Orringer A Turrisi M Iannettoni A Forastiere M Strawderman 2001 Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma J Clin Oncol 19 2 305 313
17. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335(7):462-7 (see comments) (published erratum appears in N Engl J Med. 1999 Jul 29;341(5):384).
18. DP Kelsen R Ginsberg TF Pajak DG Sheahan L Gunderson J Mortimer 1998 Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer N Engl J Med 339 27 1979 1984
19. JA Roth HI Pass MM Flanagan GM Graeber JC Rosenberg S Steinberg 1988 Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus J Thorac Cardiovasc Surg 96 2 242 248
20. JR Siewert HJ Stein M Feith BL Bruecher H Bartels U Fink 2001 Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world Ann Surg 234 3 360 367 discussion 368-9
21. PR Rohatgi SG Swisher AM Correa TT Wu Z Liao GL Walsh 2005 Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus Int J Gastrointest Cancer 36 2 69 76
22. M Kitajima Y Kitagawa 2002 Surgical treatment of esophageal cancer-the advent of the era of individualization N Engl J Med 347 21 1705 1709
23. AB Miller B Hoogstraten M Staquet A Winkler 1981 Reporting results of cancer treatment Cancer 47 1 207 214
24. CG Moertel JA Hanley 1976 The effect of measuring error on the results of therapeutic trials in advanced cancer Cancer 38 1 388 394
25. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein 2000 New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216
26. K James E Eisenhauer M Christian M Terenziani D Vena A Muldal 1999 Measuring response in solid tumors: unidimensional versus bidimensional measurement J Natl Cancer Inst 91 6 523 528
27. WA Brown J Thomas D Gotley BH Burmeister KH Lim I Martin 2004 Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy Br J Surg 91 2 199 204
28. RJ Cerfolio AS Bryant B Ohja AA Bartolucci MA Eloubeidi 2005 The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy J Thorac Cardiovasc Surg 129 6 1232 1241
29. CJ Lightdale KG Kulkarni 2005 Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer J Clin Oncol 23 20 4483 4489
30. JF Griffith AC Chan LT Chow SF Leung YH Lam EY Liang 1999 Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT Br J Radiol 72 859 678 684
31. DR Jones LA Parker Jr FC Detterbeck TM Egan 1999 Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy Cancer 85 5 1026 1032
32. M Westerterp HL van Westreenen JB Reitsma OS Hoekstra J Stoker P Fockens 2005 Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review Radiology 236 3 841 851
33. JA Ajani 2005 Carcinoma of the esophagus: is biology screaming in my deaf ears? J Clin Oncol 23 19 4256 4258
34. BLDM Brücher HJ Stein F Zimmermann M Werner M Sarbia R Busch 2004 Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial Eur J Surg Oncol 30 9 963 971
35. AJ Beer HA Wieder F Lordick K Ott M Fischer K Becker 2006 Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy Radiology 239 2 472 480
36. JL Port PC Lee RJ Korst Y Liss D Meherally P Christos 2007 Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma Ann Thorac Surg 84 393 400
37. Goldstein EB (ed) Blackwell handbook of sensation and perception, 2nd edn. Oxford: Blackwell; 2005.
38. K Hayano S Okazumi K Shuto H Matsubara H Shimada Y Nabeya 2007 Perfusion CT can predict the response to chemoradiation therapy and survival in esophageal squamous cell carcinoma: initial clinical results Oncol Rep 18 4 901 908
39. S Law DL Kwong KH Wong KF Kwok J Wong 2006 The effects of neoadjuvant chemoradiation on pTNM staging and its prognostic significance in esophageal cancer J Gastrointest Surg 10 9 1301 1311
40. AM Mandard F Dalibard JC Mandard J Marnay M Henry-Amar JF Petiot 1994 Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma Clinicopathologic correlations Cancer 73 11 2680 2686
41. M Salzer-Kuntschik G Delling G Beron R Sigmund 1983 Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80 J Cancer Res Clin Oncol 106 Suppl 21 24
42. K Junker K Langner F Klinke U Bosse M Thomas 2001 Grading of tumor regression in non-small cell lung cancer: morphology and prognosis Chest 120 5 1584 1591
43. K Becker JD Mueller C Schulmacher K Ott U Fink R Busch 2003 Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy Cancer 98 7 1521 1530
44. BLDM Brücher K Becker F Lordick U Fink M Sarbia H Stein 2006 The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas Cancer 106 10 2119 2127
45. PM Schneider SE Baldus R Metzger M Kocher R Bongartz E Bollschweiler 2005 Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification Ann Surg 242 5 684 692
46. PR Rohatgi SG Swisher AM Correa TT Wu Z Liao R Komaki 2006 Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy Cancer 106 3 552 558
47. BLDM Brücher W Weber M Bauer U Fink N Avril HJ Stein 2001 Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography Ann Surg 233 3 300 309
48. P Flamen E van Cutsem A Lerut JP Cambier K Haustermans G Bormans 2002 Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer Ann Oncol 13 3 361 368
49. L Arslan TR Miller F Dehdashti RJ Battafarano BA Siegel 2002 Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D- glucose with positron emission tomography in patients with esophageal cancer Mol Imaging 4 4 301 310
50. JR Kroep CJ van Groeningen MA Cuesta ME Craanen OS Hoekstra EF Comans 2003 Positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose for response monitoring in locally advanced gastrooesophageal cancer; a comparison of different analytical methods Mol Imaging Biol 5 5 337 346
51. RJ Downey T Akhurst D Ilson R Ginsberg MS Bains M Gonen 2003 Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial J Clin Oncol 21 3 428 432
52. S Swisher J Erasmus M Masih AM Correa H Macapinlac JA Ajani 2004 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma Cancer 101 8 1776 1785
53. JY Song JH Kim JS Ryu GH Lee SB Kim SI Park 2005 FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer Int J Radiat Oncol Biol Phys 63 4 1053 1059
54. H Kato H Kuwano M Nakajima T Miyazaki M Yoshikawa N Masuda 2002 Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer Am J Surg 184 3 279 283
55. EA Levine MR Farmer P Clark G Mishra C Ho KR Geisinger 2006 Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer Ann Surg 243 4 472 478
56. CP Duong RJ Hicks 2006 FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer Eur J Nucl Med Mol Imaging 33 7 770 778
57. MK Kim JS Ryu SB Kim JH Ahn SY Kim SI Park 2007 Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy Eur J Cancer 43 9 1385 1391
58. AA Konski JD Cheng M Goldberg T Li A Maurer JQ Yu 2007 Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma Int J Radiat Oncol Biol Phys 69 2 358 363
59. PJ Ell 2006 The contribution of PET/CT to improved patient management Br J Radiol 79 937 32 36
60. F Castell GJR Cook 2008 Quantitative techniques in 18 FDG PET scanning in oncology Br J Cancer 98 1597 1601
61. WL Wong RJ Chamberas 2008 Role of PET/PET CT in staging and restaging of thoracic oesophageal cancer and gastro-oesophageal cancer: a literature review Abdom Imaging 33 183 190
62. W Weber K Ott K Becker HJ Dittler H Helmberger NE Avril 2001 Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J Clin Oncol 19 12 3058 3065
63. H Wieder BLDM Brücher F Zimmermann K Becker F Lordick A Beer 2004 Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment J Clin Oncol 22 5 900 908
64. K Ott WA Weber F Lordick K Becker R Busch K Herrmann 2006 Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction J Clin Oncol 24 29 4692 4698
65. CM Gillham JA Lucey M Keogan GJ Duffy V Malik AA Raouf 2006 (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response Br J Cancer 95 9 1174 1179
66. F Lordick K Ott B Krause 2007 PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the Municon phase II trial Lancet Oncol 46 6 263 270
67. EA Perez M Bawejy 2008 HER2-positive breast cancer: current treatment strategies Cancer Invest 26 6 545 552
68. M Sarbia F Pühringer-Oppermann BLDM Brücher 2007 The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodal treated esophageal squamous cell carcinoma Br J Cancer 97 19 1404 1408
69. BLDM Brücher G Keller M Werner U Müller S Lassmann AD Cabras 2008 Using Q-RT-PCR to measure Cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy Int J Colorectal Dis 24 1 69 77